Understand the source comparison
Wolverine Stack Dosage Protocol: Research Application Comparison
Phase 1 (Weeks 1–2) BPC-157 250mcg/day 1.75mg BPC-157 VEGF upregulation, TNF-alpha suppression, angiogenesis initiation CRP reduction 25–40%, IL-6 reduction 15–30% Establishes anti-inflammatory baseline. Skipping this phase removes the foundation for tissue re
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase 1 (Weeks 1–2)
- BPC-157 250mcg/day
- 1.75mg BPC-157
- VEGF upregulation, TNF-alpha suppression, angiogenesis initiation
- CRP reduction 25–40%, IL-6 reduction 15–30%
- Establishes anti-inflammatory baseline. Skipping this phase removes the foundation for tissue repair signaling
- Phase 2 (Weeks 3–5)
- BPC-157 250mcg/day + TB-500 2.5mg 2×/week
- 1.75mg BPC-157 + 5mg TB-500
- Actin stabilization, fibroblast migration, extracellular matrix remodeling
- Procollagen P1NP elevation 30–50%, tissue tensile strength improvement measurable by week 5
- The critical synergy phase. Vascular networks are stabilized with structural support; dosing TB-500 without prior BPC-157 priming reduces efficacy
- Phase 3 (Weeks 6–12)
- BPC-157 250mcg/day + TB-500 2.5mg 2×/week + Ipamorelin 200mcg/day
- 1.75mg BPC-157 + 5mg TB-500 + 1.4mg Ipamorelin
- GH-mediated IGF-1 upregulation, protein synthesis amplification, collagen deposition
- IGF-1 elevation 15–25%, collagen density increase measurable via elastography, lean tissue accretion in applicable models
- Full-stack activation. Anabolic signaling layered onto established tissue architecture; this is where regenerative outcomes become functionally significant